Rezolute Inc

NASDAQ:RZLT   3:59:55 PM EDT
3.07
+0.04 (+1.32%)
Earnings Announcements

Rezolute Announces Positive Results From Phase 2B Rize Study Of RZ358 In Congenital Hyperinsulinism

Published: 03/23/2022 11:11 GMT
Rezolute Inc (RZLT) - Rezolute Announces Positive Results From the Phase 2b Rize Study of Rz358 in Congenital Hyperinsulinism.
Rezolute Inc - Rize Study Demonstrated Highly Significant Improvements in Hypoglycemia and Good Safety and Tolerability.
Rezolute Inc - Rize Study Results Will Be Presented in an Oral Presentation at an Upcoming Medical Congress in 2q 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.38

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.40

More details on our Analysts Page.